Biocept signs cnside™ licensing agreement with plus therapeutics

San diego--(business wire)---- $bioc #csf--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for cnside™ with plus therapeutics, inc. (nasdaq: pstv) (plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in june 2022. plus is using cnside in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or m.
BIOC Ratings Summary
BIOC Quant Ranking